UCB Pushes On With Potential Myasthenia Gravis Therapy, But Competition Looms

 
• By John Davis

The anti-FcRn MAb, rozanolixizumab, has been found to be effective in myasthenia gravis and has potential in ITP, but other companies are also developing potential therapeutic candidates for such auto-immune conditions.  

Acceleration
The development of rozanolixizumab is to be accelerated. • Source: Shutterstock

More from Neurological

More from Therapy Areas